RXSIGHT INC. DL -,001

At the Wells Fargo Healthcare Conference, new CEO Aziz Mottiwala presented a strategic realignment plan to intensify use of the light‑adjustable lens (LAL) among existing surgeons and to double U.S. sales through internal reallocations. The partnership closed in July with Alcon includes a $200 million upfront payment and a 30% royalty on future sales, plus access to Alcon’s sales network. RxSight has about $210 million in cash (excluding the full Alcon payment), high gross margins, and is working on a next‑generation LAL; the company is targeting a return to growth in 2027 but has not provided concrete forecasts. » Plus sur de.investing.com

RxSight appointed Aziz Mottiwala, effective July 20, as president and chief executive officer; he replaces Dr. Ron Kurtz, who will move to chief medical officer and leave the board of directors, while Mottiwala will be named to the board. Mottiwala joins from Tarsus Pharmaceuticals and brings experience in senior sales and commercial roles in ophthalmology. The stock is under pressure (about −8% last week, −50% over six months) and is trading at $5.25 (market capitalization $216.92 million). The company manufactures the Light Adjustable Lens System and said it would not change its prior financial guidance. » Plus sur de.investing.com

RxSight lowered its 2026 revenue forecast to $110–120 million (previously $120–135 million), triggering a roughly 12.9% share price decline. The total revenue outlook of $140–160 million includes $30–40 million from the Alcon collaboration; preliminary Q2 revenues are expected at $32–34 million ( $5–7 million from the Alcon partnership, about $27 million from product sales). The company cited "significant commercial headwinds" and plans to accelerate sales investments while maintaining spending discipline; gross margin guidance was raised to 73–75%, and operating expenses remain at the high end of the $150–160 million range. Cash and equivalents totaled about $209 million as of June 30; RxSight is working on a next generation of Light Adjustable Lens products. » Plus sur de.investing.com